Literature DB >> 36030475

ABCC6P1 pseudogene induces ABCC6 upregulation and multidrug resistance in breast cancer.

Mahnaz Hashemi1, Masoud Golalipour2,3.   

Abstract

BACKGROUND: The elevated drug efflux by ABC transports has been considered the primary mechanism of drug resistance in cancer. Recently, non-coding RNAs, such as pseudogenes, have been proposed to be involved in transporter-mediated drug resistance in cancer. The human genome has 22 ABC transporter pseudogenes. Among these pseudogenes, ABCC6P1 has co-expression with its ancestral gene in various human tissues. In the present study, we assessed the effect of ABCC6P1 pseudogene overexpression on ABCC6 expression and drug resistance. METHODS AND
RESULTS: The ABCC6P1 was transfected into the MCF-7 and MDA-MB-231 cells. In ABCC6P1-overexpressing cells, the ABCC6 level significantly increased. The results of cell treatment with doxorubicin, 5-fluorouracil, cisplatin, and paclitaxel showed that the survival of ABCC6P1-overexpressing cells was higher than normal cells. Furthermore, uptake of doxorubicin was lower in ABCC6P1-overexpressing cells.
CONCLUSIONS: In conclusion, our results show that overexpression of ABCC6P1 pseudogene induces the drug resistance phenotype, possibly through activation of the ancestral gene.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  ABCC6; ABCC6P1; Breast cancer; Drug resistance; Pseudogene

Mesh:

Substances:

Year:  2022        PMID: 36030475     DOI: 10.1007/s11033-022-07872-6

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.742


  25 in total

1.  Long non-coding RNA LUCAT1 modulates methotrexate resistance in osteosarcoma via miR-200c/ABCB1 axis.

Authors:  Zhe Han; Liying Shi
Journal:  Biochem Biophys Res Commun       Date:  2017-11-21       Impact factor: 3.575

2.  lncRNA UCA1 Contributes to Imatinib Resistance by Acting as a ceRNA Against miR-16 in Chronic Myeloid Leukemia Cells.

Authors:  Yun Xiao; Changjie Jiao; Yiqiang Lin; Meijun Chen; Jingwen Zhang; Jiajia Wang; Zhongying Zhang
Journal:  DNA Cell Biol       Date:  2016-11-17       Impact factor: 3.311

Review 3.  ABC Family Transporters.

Authors:  Xiaodong Liu
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 4.  ABC Transporter-Mediated Multidrug-Resistant Cancer.

Authors:  Haneen Amawi; Hong-May Sim; Amit K Tiwari; Suresh V Ambudkar; Suneet Shukla
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

5.  Cancer Statistics, 2021.

Authors:  Rebecca L Siegel; Kimberly D Miller; Hannah E Fuchs; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2021-01-12       Impact factor: 508.702

6.  LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145.

Authors:  Rongrong Gao; Chun Fang; Jichong Xu; Huaqiao Tan; Peng Li; Lin Ma
Journal:  Arch Biochem Biophys       Date:  2019-01-09       Impact factor: 4.013

7.  TGF-β1 elevates P-gp and BCRP in hepatocellular carcinoma through HOTAIR/miR-145 axis.

Authors:  Jiehong Kong; Yajing Qiu; Yuan Li; Hongjian Zhang; Weipeng Wang
Journal:  Biopharm Drug Dispos       Date:  2019-02-18       Impact factor: 1.627

8.  Gene dosage is not responsible for the upregulation of MRP1 gene expression in adult leukemia patients.

Authors:  Masoud Golalipour; Frouzandeh Mahjoubi; Mohammad Hossein Sanati; Kamran Alimoghaddam; Alimoghaddam Kamran
Journal:  Arch Med Res       Date:  2007-04       Impact factor: 2.235

9.  Expression of MRP1 gene in acute leukemia.

Authors:  Frouzandeh Mahjoubi; Masoud Golalipour; Ardeshir Ghavamzadeh; Kamran Alimoghaddam
Journal:  Sao Paulo Med J       Date:  2008-05-01       Impact factor: 1.044

Review 10.  The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer.

Authors:  Yu Wang; Yingying Wang; Zhiyuan Qin; Sheng Cai; Lushan Yu; Haihong Hu; Su Zeng
Journal:  Expert Opin Drug Metab Toxicol       Date:  2021-02-22       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.